Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with poor
prognosis. Surgery, chemotherapy, and radiofrequency ablation are three conventional …

More than 90% of cases of hepatocellular carcinoma (HCC) occurs in patients with cirrhosis,
of which hepatitis B virus and hepatitis C virus are the leading causes, while the tumor less …

Hepatocellular carcinoma (HCC) is the most common type of liver cancer and one of the
leading causes of cancer-related death worldwide. Advanced HCC displays strong …

Hepatocellular carcinoma (HCC) is one of the world's deadliest and fastest-growing tumors,
with a poor prognosis. HCC develops in the context of chronic liver disease. Curative …

In recent years, the role of optically sensitive nanomaterials has become powerful moieties
in therapeutic techniques and has become particularly emphasized. Currently, by the …

Hepatocellular carcinoma (HCC) is one of most common cancers and the fourth leading
cause of death worldwide. Commonly, HCC development occurs in a liver that is severely …

Hepatocellular carcinoma (HCC) is a chronic liver disease that is highly fatal if not detected
and treated early. The incidence and death rate of HCC have been increasing in recent …

Independent of tumor type and non‐invasive or minimally‐invasive feature, current physical
treatments including ultrasound therapy, microwave ablation (MWA), and radiofrequency …

Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death worldwide.
Local ablation, such as radiofrequency ablation, microwave ablation, cryoablation and …

Purpose: Immunotherapy for hepatocellular carcinoma (HCC) shows considerable promise
in improving clinical outcomes. HepaVac-101 represents a single-arm, first-in-human phase …